13G Filing: Tangiers Global, Llc and Endonovo Therapeutics Inc. (ENDV)

CUSIP No. 29272H201

13G

Page 3 of 5 Pages

Item 1

(a)

Name of lssuer:

Endonovo
Therapeutics, Inc.

(b)

Address Of Issuer’s Principal Executive Offices:

6320
Canoga Avenue, 15h Floor, Woodland Hills, CA 91367

 

Item 2

(a)

Name of Person Filing:

TANGIERS GLOBAL, LLC.

(b)

Address of Principal Business Office, or, if none, Residence:

Caribe Plaza Office Building 6^th
Floor, Palmeras St. #53

San Juan, PR 00901

(c)

Citizenship:

Wyoming

(d)

Title of Class of Securities:

Common Stock, $.0001 value per
share

(e)

Cusip Number:

29272H201

 

Item 3

If this statement is filed pursuant to §240.13d-I(b) or 240.13d-2(b) or (c), check whether the person filing is a:

	(a)	¨	Broker or dealer registered under section 15 of the Act (15 U.S.C, 78o).
	(b)	¨	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	¨	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	¨	Investment company registered under section 8 of the Investment Company Act (15 U.S.C.80a-8).
	(e)	¨	An investment adviser in accordance with §240.13d-l(b)(l)(ii)(E).
	(f)	¨	An employee benefit plan or endowment fund in accordance with §240.13d-l(b)(ii)(F).
	(g)	¨	A parent holding company or control person in accordance with §240.13d-l(b)(l)(ii)(G).
	(h)	¨	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813).
	(i)	¨	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	¨	Group in accordance with §240.13d-l(b)(ii)(J).